Pet owners have rallied to help ASX-listed PharmAust start to evaluate the effects of its newly formulated anti-cancer drug, Monepantel on dogs suffering from B-cell lymphoma in a planned phase IIb clinical trial. The Perth-based company, who hopes to further substantiate Monepantel’s tumour-reduction qualities, says several hounds have already been successfully recruited and have commenced treatment with Monepantel tablets.
15/02/2021 - 16:24
PharmAust recruits first dogs for anti-cancer drug trial
By Matt Birney
15/02/2021 - 16:24
Related Data & Insights
-
-
Rank Company Revenue 128th PharmAust $3.8m 129th ResApp Health $3.8m 130th Emyria $3.8m 132nd Botanix Pharmaceuticals $3.8m 133rd Volt Power Group $3.6m 200 listed industrial wa companies ranked by revenue.
Powered by Morningstar ®
Data & Insights
Mentioned Organisations
Mentioned People
Related Articles
05 Feb 2024
Board Moves February 5, 2024
28 Aug 2023
Board Moves August 28, 2023
Subscribe today for award-winning, unbiased and trusted journalism
Subscription OptionsX